Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
6.01
-0.13 (-2.12%)
At close: Dec 5, 2025, 4:00 PM EST
5.95
-0.06 (-1.00%)
After-hours: Dec 5, 2025, 7:10 PM EST
Dogwood Therapeutics Employees
Dogwood Therapeutics had 12 employees as of December 31, 2024. The number of employees increased by 8 or 200.00% compared to the previous year.
Employees
12
Change (1Y)
8
Growth (1Y)
200.00%
Revenue / Employee
n/a
Profits / Employee
-$3,331,297
Market Cap
13.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DWTX News
- 4 days ago - Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 - Accesswire
- 25 days ago - Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 - Accesswire
- 4 weeks ago - Dogwood Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Accesswire
- 7 weeks ago - Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 - Accesswire
- 2 months ago - Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit - Accesswire
- 2 months ago - Dogwood Therapeutics, Inc. - Special Call - Seeking Alpha
- 2 months ago - Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients - GlobeNewsWire